Scientists are reporting the first clear success with a new approach for treating leukemia — turning the patients' own blood cells into assassins that hunt and destroy their cancer cells www.foxnews.com
New Treatments Tube. Duration : 0.85 Mins.
New Treatments www.mesorc.com/mesothelioma/new-treatments/ Although surgery, radiation therapy, and chemotherapy have improved overall mesothelioma survival rates, there is still no cure for this deadly disease. Today, new mesothelioma treatment methods are being developed and studied in clinical trials. Below are a few of these newer treatments for mesothelioma. Intracavitary Chemotherapy Intracavitary chemotherapy is a new approach to mesothelioma chemotherapy in which medication is placed directly into body cavities. With this new treatment for mesothelioma, medication can be administered at much higher doses than traditional alternate chemotherapy. Intracavitary chemotherapy is also thought to allow chemotherapy medication to enter tumor cells directly, without the toxic side effects of traditional chemotherapy. Drugs Since chemotherapy agents have not proven to be very effective in treating advanced mesothelioma, doctors are currently testing new drugs. These new mesothelioma treatments include medications which kill cancers by depriving them of blood supply, such as bevacizumab (Avastin). Anti-growth factor drugs such as erlotinib (Tarceva) are also being studied. These inhibit the growth of mesothelioma cancer cells. Another promising new mesothelioma treatment, Alimta(R), was approved by the FDA in 2004. When used in combination with the anti-cancer drug cisplatin, it has been shown to drastically improve symptoms for some mesothelioma patients. Clinical trials …
Keywords: New, Treatments treatmentofmesothelioma.paktumblog.com
One of the most fatal types of mesothelioma is peritoneal mesothelioma, in which cancer cells to attack the peritoneum as the peritoneum. Peritoneum is the thin membrane that protects the various organs of the abdomen and also provides a lubricating fluid to enable the organs to move and work properly. Peritoneal mesothelioma, which affects the lining, it is still a relatively rare disease, about 1 / 5 accounts of all mesotheliomas. His only knownBecause the United States to date is previous exposure to asbestos.
The major symptoms
Although mesothelioma is neither age nor sex-specific peritoneal mesothelioma is usually in men can be seen in the age group of 50-70 years. There are a number of symptoms of peritoneal mesothelioma most of which appear at a distance of 20 years, 30 or 50 after exposure to asbestos to get started. These symptoms may include weight loss (but may increase the life), pain or swellingAbdomen, weakness, loss of appetite, intestinal obstruction, anemia, nausea and fever. In addition, the fluid often accumulates in the peritoneal cavity leads to a condition called ascites.
Peritoneal mesothelioma – cancer of the peritoneum
The diagnosis of peritoneal mesothelioma
The first step towards the identification of peritoneal mesothelioma includes X-rays and CT scans. Able to confirm the diagnosis, but the doctor needs to do a biopsy, which is cut a piece of tissue from the affected part of the body of the victim andMicroscope for examination. If the disease is diagnosed at an early stage, stands a better chance that the state of diffuse peritoneal mesothelioma, where the cancer has already spread to different parts healed.
It 'true that the peritoneal mesothelioma fatal and leads to several deaths every year. But with the continuing research, have followed different methods of treatment and in the future there is a fair chance of diseasealways completely curable. The type of treatment of peritoneal mesothelioma include surgery, radiation therapy and chemotherapy.
In surgery, a portion of the abdominal tissue is made, cut to remove the tumor. Sometimes the doctor may need a lung or a portion of the diaphragm according to the requirement for surgery to remove. Radiotherapy, the second method requires the use of high-energy X-rays to shrink tumors and kill cancer cells. Radiation canApplying an external computer or the source of radiation directly on the affected part of the body through plastic tubes. Last type of treatment is chemotherapy using a combination of drugs to kill cancer cells. Medications can be administered orally in capsule form or can be used intravenously by August
However, it is important to remember that the cost is extravagant to treat a form of cancer and you can consult a mesotheliomaLawyer, you get a nice compensation from the authority, which was your previous exposure to asbestos.
To learn more about peritoneal mesothelioma so that you can start treatment at a very early stage and treated.
Peritoneal mesothelioma – cancer of the peritoneum
Mesothelioma Doctor Explains Symptoms, Diagnosis & Treatment Tube. Duration : 1.87 Mins.
Mesothelioma Video from www.mesothelioma.us In this video a medical doctor explains types of mesothelioma. In the full DVD he explains mesothelioma stages, mesothelioma types, mesothelioma symptoms, and mesothelioma diagnosis. Most importantly mesothelioma treatments are discussed. This…
Keywords: asbestos cancer, mesothelioma, cancer, asbestos treatmentofmesothelioma.paktumblog.com
Among elderly patients with squamous cell skin cancer that could not be surgically removed, treatment with the targeted therapy Erbitux® (cetuximab) produced a promising rate of disease control. The results of this Phase II clinical trial were published in the Journal of Clinical Oncology.
Non-melanoma skin cancer refers to all types of skin cancer other than melanoma. Although there are several different types of non-melanoma skin cancer, the two most common types are basal cell carcinoma and squamous cell carcinoma.
Squamous cell carcinoma accounts for roughly 20% of all cases of non-melanoma skin cancer. Squamous cell carcinoma commonly involves the head or neck. The tumor may appear as a red bump or as a rough or scaly area on the skin. Squamous cell carcinoma is more likely than basal cell carcinoma to spread to lymph nodes or distant parts of the body, though this happens infrequently.
Treatment of squamous cell skin cancer often involves surgery to remove the cancer. This may not be possible for some patients, however, and other treatment approaches will need to be considered.
Erbitux is a targeted therapy that inhibits growth of the cancer by binding to a portion of the epidermal growth factor receptor (EGFR), a protein located on the surface of many cancer cells. Erbitux is currently approved for the treatment of selected patients with advanced head and neck cancer or advanced colorectal cancer.
To asses Erbitux in the treatment of squamous cell skin cancer, researchers conducted a Phase II clinical trial among 36 patients. Half the patients were over the age of 79 years, and all had squamous cell skin cancer that could not be surgically removed. Study participants were treated with Erbitux for at least six weeks.
After six weeks, 69% of patients had cancer that had either improved or remained stable.
Out of the 36 patients, eight had a partial reduction in cancer and two had a complete disappearance of detectable cancer.
There were no treatment-related deaths, but there were three serious adverse events (two infusion reactions and one lung problem).
A majority of patients (78%) experienced an acne-like rash.
These results suggest that Erbitux is active against squamous cell skin cancer, and may provide an option for patients with cancer that cannot be surgically removed. The researchers recommend a Phase III clinical trial in order to further evaluate Erbitux for this purpose.
Reference: Maubec E, Petrow P, Scheer-Senyarich I et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. Journal of Clinical Oncology. Early online publication August 1, 2011. news.cancerconnect.com
• Uses HER2 as a target to selectively deliver toxins to cancer cells.
• Designed to overcome issues of resistance with Herceptin.
PHILADELPHIA — Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Jacek Capala, Ph.D., D.Sc., an investigator at the National Cancer Institute, and colleagues designed, produced and tested HER2-Affitoxin, a novel protein that combines HER2-specific affibody molecules and a modified bacterial toxin, PE38.
“Unlike the current HER2-targeted therapeutics, such as Herceptin, this protein does not interfere with the HER2 signaling pathway but, instead, uses HER2 as a target to deliver a modified form of bacterial toxin specifically to the HER2-positive cancer cells. When cells absorb the toxin, it interferes with protein production and, thereby, kills them,” said Capala.
At least, that is what happened in Capala’s laboratory. After Affitoxin was injected into tumor-bearing mice, even relatively large, aggressive tumors stopped growing and most of them disappeared. The effect was strong enough that Capala believes it warrants a clinical trial.
“Herceptin has revolutionized the treatment of patients with HER2-positive breast cancer, but a significant number of tumors acquire resistance to the drug,” said Capala. “Affitoxin could offer another therapeutic option for those patients whose tumors no longer respond to Herceptin.”
# # #
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
You can link to this article on your web site using following code:
We're looking for comments that are interesting, substantial or highly amusing. If your comments are excessively self-promotional (use your real name, no keywords please), obnoxious, or even worse, boring, you will be banned from commenting. Your comment must be related to the post. Please do not comment on how great or wonderful the post is. All comments are moderated and, if approved, will display in less than 24 hours.